Equities analysts expect that QIAGEN (NYSE:QGEN) will report $0.65 earnings per share for the current quarter, Zacks reports. Four analysts have made estimates for QIAGEN’s earnings. The highest EPS estimate is $0.67 and the lowest is $0.62. QIAGEN posted earnings per share of $0.55 during the same quarter last year, which would suggest a positive year over year growth rate of 18.2%. The business is scheduled to report its next earnings results after the market closes on Thursday, July 29th.
On average, analysts expect that QIAGEN will report full year earnings of $2.44 per share for the current fiscal year, with EPS estimates ranging from $2.42 to $2.47. For the next year, analysts anticipate that the company will report earnings of $2.06 per share, with EPS estimates ranging from $1.98 to $2.20. Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that cover QIAGEN.
QIAGEN (NYSE:QGEN) last issued its earnings results on Sunday, May 2nd. The company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.63 by $0.03. QIAGEN had a net margin of 21.72% and a return on equity of 21.06%. The business had revenue of $567.21 million for the quarter, compared to analysts’ expectations of $557.57 million. During the same quarter in the previous year, the firm posted $0.34 EPS.
QGEN stock traded up $0.55 during midday trading on Friday, reaching $51.05. 3,812 shares of the company’s stock traded hands, compared to its average volume of 891,781. The firm has a 50-day moving average price of $48.17. The company has a debt-to-equity ratio of 0.68, a current ratio of 3.34 and a quick ratio of 2.70. QIAGEN has a 52 week low of $45.33 and a 52 week high of $59.00. The stock has a market capitalization of $11.64 billion, a price-to-earnings ratio of 26.30, a PEG ratio of 1.80 and a beta of 0.24.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Massachusetts Financial Services Co. MA boosted its position in QIAGEN by 38.7% during the first quarter. Massachusetts Financial Services Co. MA now owns 16,339,338 shares of the company’s stock valued at $795,563,000 after buying an additional 4,556,336 shares during the period. FIL Ltd raised its stake in shares of QIAGEN by 35.4% during the fourth quarter. FIL Ltd now owns 5,903,112 shares of the company’s stock valued at $304,293,000 after acquiring an additional 1,544,763 shares during the last quarter. BlackRock Inc. raised its stake in shares of QIAGEN by 4.3% during the first quarter. BlackRock Inc. now owns 4,897,390 shares of the company’s stock valued at $238,453,000 after acquiring an additional 200,049 shares during the last quarter. Norges Bank bought a new position in shares of QIAGEN during the fourth quarter valued at about $208,212,000. Finally, Goldman Sachs Group Inc. raised its stake in shares of QIAGEN by 73.7% during the first quarter. Goldman Sachs Group Inc. now owns 2,279,362 shares of the company’s stock valued at $110,982,000 after acquiring an additional 966,935 shares during the last quarter. Institutional investors and hedge funds own 52.13% of the company’s stock.
QIAGEN Company Profile
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits designed for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.
Featured Article: What is the formula for calculating total return?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for QIAGEN Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for QIAGEN and related companies with MarketBeat.com's FREE daily email newsletter.